| 标题： | 胶质瘤分子检测中国专家共识 |
| title： | Consensus of Chinese Experts on Molecular Detection of Gliomas |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 专家共识 |
| classification： | Experts consensus |
| 领域： | 诊断 |
| field： | Diagnosis |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 神经病理医师 |
| Guide users： | Neuropathologist |
| 证据分级方法： | 参考推荐等级的评估、制订和评价（GRADE）方法，分为“强烈推荐”和“推荐”。其中专家组投“非常同意”的票数超过2/3的意见为“强烈推荐”，专家组投“非常同意”+“基本同意”的票数超过2/3的意见为“推荐”，否则不达成共识。 |
| Evidence grading method： | The evaluation, formulation, and evaluation (GRADE) method for reference recommendation levels is divided into "strongly recommended" and "recommended". Among them, opinions with more than two-thirds of the votes cast by the expert group for "strongly agree" are considered "strongly recommended", and opinions with more than two-thirds of the votes cast by the expert group for "strongly agree"+"basically agree" are considered "recommended". Otherwise, consensus will not be reached. |
| 制定单位： | 中华医学会病理学分会神经病理学组 |
| Formulating unit： | Neuropathology Group, Chinese society of pathology |
| 注册时间： | 2024-06-21 |
| Registration time： | |
| 注册编号： | PREPARE-2024CN855 |
| Registration number： | |
| 指南制订的目的： | 长期以来，以组织学为基础的中枢神经系统（CNS）肿瘤的病理诊断作为诊断的“金标准”，在中枢神经系统肿瘤的诊断、治疗、预后评估方面发挥着重要作用。自2021年第五版中枢神经系统肿瘤WHO分类指南公布以来，越来越多的分子指标被纳入胶质瘤病理整合诊断，已成为日常病理诊断不可或缺的一部分。整合诊断及分子标记物的应用为提高神经病理诊断的客观性和可重复性、完善个体化治疗、促进临床试验和基础研究等发挥着重要的作用，但也给日常病理诊断实践带来巨大挑战；相关分子指标涉及基因变异形式多样，不同检测方法结果存在差异，缺乏针对胶质瘤分子检测范围、技术局限性及检测路径的专家共识，因此，由具有丰富理论及实践经验的神经病理、分子病理专家共同发起并制定本共识，旨在为胶质瘤精准病理诊疗提供全面的指导和建议。 |
| Purpose of the guideline： | For a long time, the pathological diagnosis of central nervous system (CNS) tumors were based on histology, playing an important role in the diagnosis, treatment, and prognosis evaluation of CNS tumors. Since the publicaition of the fifth edition of the WHO classification for central nervous system tumors in 2021, an increasing number of molecular signatures have been incorporated into the pathological integrated diagnosis of gliomas, becoming an indispensable part of daily pathological diagnosis. The application of integrated diagnosis and molecular signatures plays an important role in improving the objectivity and reproducibility of neuropathological diagnosis, improving individualized treatment, promoting clinical trials and basic research, but it also brings huge challenges to daily pathological diagnosis practice; The relevant molecular signaturess involve various forms of genetic variation, and there are differences in the results of different detection methods. There is a lack of expert consensus on the scope, technical limitations, and detection pathways of molecular detection for gliomas. Therefore, this consensus is jointly initiated and developed by experts in neuropathology and molecular pathology with rich theoretical and practical experience, aiming to provide comprehensive guidance and suggestions for the precise pathological diagnosis and treatment of gliomas. |
最新注册
